BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 11, Issue 8
  • This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (4243)
All Articles published online
The chart showing PDF series, HTML series, Tables (1-3) series.
Item 
Count 
PDF458
HTML3295
Tables (1-3)490
 Sum=4243
Feb 28, 2005 (publication date) through Nov 16, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1187-1192
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1187
Table 1 Genotype frequencies of the IBD5 SNPs in Crohn’s disease patients and controls.
TT (%)GT (%)GG (%)
Controls (n = 511)170 (33.3)236 (46.2)105 (20.5)
CD patients (n = 274)74 (27)136 (49.6)64 (23.4)
CD-L1 (n = 133) terminal ileum + UG41 (30.8)66 (49.6)26 (19.6)
CD-L2 (n = 46) colon12 (26.1)23 (50)11 (23.9)
CD-L3 (n = 95) ileocolon21 (22.1)47 (49.5)27 (28.4)a
CD-B1 (n = 119) inflammatory36 (30.2)60 (50.4)23 (19.3)
CD-B2 (n = 44) stricturing14 (31.8)22 (50)8 (18.2)
CD-B3 (n = 110) fistulizing24 (21.3)53 (48.9)33 (30)c
CD-perianal (n = 47)10 (21.3)23 (48.9)14 (29.8)
CD-non perianal (n = 227)64 (28.2)113 (49.8)50 (22)
(GG+ GT) vs TT:
aP<0.05; OR (CI) = 1.76 (1.02-3.05) compared to controls. (GG+ GT) vs TT:
cP<0.05; OR (CI) = 1.79 (1.07-3.00) compared to controls.
Full Size Table
Table 2 Genotype frequencies of the IBD5 SNPs in NOD2/CARD15-negative Crohn’s disease patients and ethnically-matched controls.
TT (%)GT (%)GG (%)
Controls (n = 511)170 (33.3)236 (46.2)105 (20.5)
CD patients (n = 140)32 (22.9)69 (49.3)39 (27.9)a
CD-L1 (n = 55) terminal ileum + UG16 (29.1)25 (45.5)14 (25.5)
CD-L2 (n = 31) colon8 (25.8)15 (48.4)8 (25.8)
CD-L3 (n = 54) ileocolon8 (14.8)29 (53.7)17 (31.5)b
CD-B1 (n = 65) inflammatory17 (26.1)33 (50.8)15 (23.1)
CD-B2 (n = 15) stricturing6 (40)7 (46.7)2 (13. 3 )
CD-B3 (n = 59) fistulizing9 (15.25)28 (47.5)22 (37.3)d
CD-perianal (n = 34)6 (17.7)19 (55.9)9 (26.5)
CD-non perianal (n = 106)26 (24.5)50 (47.2)30 (28.3)
(GG+GT) vs TT:
aP<0.05; OR (CI) = 1.68 (1.07-2.66) compared to controls. (GG+GT) vs TT:
bP<0.01; OR (CI) = 2.87 (1.27-6.73) compared to controls. (GG+GT) vs TT:
dP<0.01; OR (CI) = 2.77 (1.28-6.2) compared to controls.
Full Size Table
Table 3 Patients’ characteristics at the time of infliximab treatment: the differential response to infliximab therapy in CD patients depends on their 5q31 genotype.
Responder (n = 25)Non-responder (n = 15)P
Demographics
Mean age, yr (range)35 (21-66)40 (17-68)0.21
Mean duration of disease, yr (range)10 (1-27)12 (1-31)0.37
Male:Female13:126:090.46
Smoker, n (%)13 (52)8 (53.3)0.93
Extraintestinal13 (52)7 (46)0.92
manifestations, n (%)
Previous surgery, n (%)14 (56)9 (60)0.8
Disease distribution
Small bowel only, n (%)9 (36)4 (26.7)0.54
Colon only, n (%)3 (12)2 (13.3)1
Colon and small bowel, n (%)13 (52)9 (66)0.62
Indication for infliximab
Inflammatory disease only, n (%)7 (28)6 (40)0.62
Fistulizing disease only, n (%)10 (40)7 (46.7)1
Inflammatory and8 (32)2 (13.3)0.27
fistulizing disease, n (%)
Concomitant medication
6-mercaptopurine, azathioprine,17 (68)13 (86.7)0.27
methotrexate, n (%)
Mesalamine, n (%)7 (28)4 (26.7)0.52
Corticosteroid, n (%)6 (24)5 (33.3)1
5q31 genotype
Homozygous wild type, n (%)6 (24)3 (20)1
Heterozygous, n (%)16 (64)5 (33.3)0.1
Homozygous mutant, n (%)3 (12)7 (46.7)0.024a
aP<0.05, RR (CI) = 3.88 (1.18-12.8).
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345